Published June 14, 2010 | Version v1
Journal article Metadata-only

Serum Biomarkers for Early Detection of Gynecologic Cancers

Creators

  • 1. Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, 565-0871 (Japan)

Description

Ovarian, endometrial, and cervical cancers are three of the most common malignancies of the female reproductive organs. CA 125, historically the most reliable serum marker for ovarian cancer, is elevated in 50% of early-stage ovarian tumors. For endometrial cancers, there are no established serum markers. SCC, which is the best studied serum marker for squamous cell carcinomas, has been unreliable; SCC is elevated in cervical squamous cell carcinomas ranging from 28–85% of the time. Recent proteomics-based analyses show great promise for the discovery of new and more useful biomarkers. In this review, we will discuss the currently utilized serum tumor markers for gynecologic cancers and the novel biomarkers that are now under investigation

Availability note (English)

Available from http://dx.doi.org/10.3390/cancers2021312; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3835131

Additional details

Identifiers

URL
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3835131;
DOI
10.3390/cancers2021312;

Publishing Information

Journal Title
Cancers (Basel)
Journal Volume
2
Journal Issue
2
Journal Page Range
p. 1312-1327
ISSN
2072-6694

INIS

Country of Publication
Switzerland
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
47001894
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
BIOLOGICAL MARKERS; CARCINOMAS; NEOPLASMS; OVARIES
Descriptors DEC
BODY; DISEASES; FEMALE GENITALS; GONADS; NEOPLASMS; ORGANS

Optional Information

Copyright
Copyright (c) 2010 by the authors
Notes
PMCID: PMC3835131; PMID: 24281117; PUBLISHER-ID: cancers-02-01312; OAI: oai:pubmedcentral.nih.gov:3835131; licensee MDPI, Basel, Switzerland.; This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).